New recommendation: antidepressants for PMS

accreditation

Antidepressants are the first treatment choice for a severe type of premenstrual syndrome associated with suicidal thoughts, according to a new research review.

Up to 8 percent of women with PMS have this condition, called premenstrual dysphoric disorder, or PMDD, according to researchers who evaluated 31 published studies on it.

Important recommendations

Any woman with "depression, hopelessness, and self-deprecating thoughts that occur in the final week before the onset of menses" should see that as a warning sign to consult her physician, said study author Kenneth Trevino, a psychologist at University of Texas Southwestern Medical Centre in Dallas.

Options for treating PMDD include birth control pills, psychiatric drugs like antidepressants, and supplements such as saffron, calcium and ginkgo biloba, the researchers say in background notes.

The researchers' "reasonable and evidence-based" recommendations are important because "rather than just being a nuisance, PMDD interferes with a woman's ability to 'do life'", said Dr Christine Isaacs, a division head of the Virginia Commonwealth University's department of obstetrics and gynaecology, who wasn't involved in the study.

Trevino and his co-author Shalini Maharaj, also at UT Southwestern, looked at the evidence supporting different therapies. They recommended that antidepressants called selective serotonin reuptake inhibitors, or SSRIs, should be the first choice for a woman with PMDD.

This class of drugs includes Paxil, Zoloft and Prozac.

Serotonin is a nerve signalling chemical, or neurotransmitter, related to mood. SSRIs help keep this chemical available longer for brain cells to use, according to researchers.

Trevino and Maharaj analysed studies looking at these antidepressants in almost 4,400 women with PMDD or premenstrual syndrome. Their recommendations were published in the September issue of the Journal of Psychiatric Practice.

Cyclic in nature

Hormonal changes during the menstrual cycle can affect serotonin levels, which is one factor in PMDD, said the study authors. About 60 to 70 percent of women with PMDD will experience improvement with an SSRI, Trevino noted.

In general, PMDD differs from premenstrual syndrome by involving several symptoms just before a period starts, including mood-related problems such as anger, anxiety or depressed mood, and physical symptoms such as low energy or appetite, headaches or sleeplessness, Trevino said.

Read: Contraception for your teenage daughter

Isaacs also looks for repeated bouts of these issues in patients. "I would expect these symptoms to repeat and be cyclic in nature," she said. "Often, I find women will come speak to me after the encouragement of a family member or loved one who is worried about them, having observed this pattern on multiple occasions."

Trevino said the primary factor that should be considered is symptom severity, especially a woman's current level of emotional distress. "The greater the symptom severity, the more important it is to start with the most effective or established treatment option, which would be an SSRI," he said.

However, SSRIs are not for everyone. Just this week, a study published in the British Medical Journal concluded that Paxil (paroxetine) is not safe for teens with major depression, increasing their risk of suicidal behaviour and self-harm.

Trevino said the 30 to 40 percent of women with PMDD who don't benefit from antidepressants might try other treatment options, such as anti-anxiety medications or hormonal contraceptives. Indeed, contraceptives can be considered for a woman who wants to start birth control anyway, he said.

More research needed

For other patients, "I may incorporate multiple modalities, such as SSRI and calcium, and recommend an exercise regimen," said Isaacs. "It requires some trial and error at first and close follow-up with a trusted provider."

Read: The latest contraceptive options for women

The researchers found that calcium supplementation appears helpful for women with PMDD.

Options such as saffron and ginkgo biloba showed some promise in initial trials but need more research, said the authors. Behavioural therapies don't seem to produce much improvement, they found.

Dietary factors like caffeine and "carbohydrate-rich" beverages seemed to have some benefit for mood in women with premenstrual syndrome, the authors wrote. Results with exercise are "encouraging" but also require more study, they said.

The last-ditch choice when other options don't work is a drug that brings on "medical menopause", but these medications are costly and can have unpleasant, menopause-like side effects, said the authors.

All of the possible therapies have their pros and cons, said Isaacs. "As a general philosophy, I try to incorporate the safest, least-invasive options first," she said.

Read more:

B vitamin-rich food lowers risk of PMS

Obese teens less likely to use birth control

Newer birth control pills may raise blood clot risk

Image: Antidepressants in a hand from Shutterstock

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
The ANC's leadership race is heating up. Who do you think will be elected party president at Nasrec in December?
Please select an option Oops! Something went wrong, please try again later.
Results
Nkosazana Dlamini-Zuma has got it in the bag
6% - 214 votes
I foresee a second term for Cyril Ramaphosa
81% - 2783 votes
Don’t discount a Zweli Mkhize win
12% - 420 votes
Vote
Rand - Dollar
17.96
-0.7%
Rand - Pound
19.94
-2.6%
Rand - Euro
17.60
-1.3%
Rand - Aus dollar
11.66
-0.2%
Rand - Yen
0.12
-0.4%
Gold
1,659.71
-0.0%
Silver
18.82
-0.4%
Palladium
2,201.50
+2.4%
Platinum
868.00
+0.2%
Brent Crude
89.32
+3.4%
Top 40
56,921
-0.9%
All Share
63,264
-0.9%
Resource 10
59,793
+3.2%
Industrial 25
76,769
-2.3%
Financial 15
13,707
-2.9%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE